Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

In this mouse study, the researchers found that the monoclonal antibody ME1 causes hair follicle inflammation by up-regulating TNFα, which can be reduced by TNFα and interleukin-1 inhibitors.

This study found that TNFα inhibitors can induce psoriatic alopecia, highlighting that early diagnosis and discontinuation of the drugs in some cases may prevent irreversible scalp damage.

This review discusses current anti-inflammatory treatment options for calcium pyrophosphate crystal deposition disease (CPPD) and highlights the lack of crystal-targeted therapies, emphasizing the need for more research to guide treatment.

Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.

This quiz based on a Journal of Investigative Dermatology article reports no new clinical results but serves as an educational tool for diagnosing scalp conditions, including scalp psoriasis and psoriatic alopecia.

This review details the adverse effects and drug interactions of biologic agents used in rheumatoid disease treatment, highlighting their significant side effect profile without reporting new clinical findings.

This study describes a case where stopping infliximab and using oral minocycline with topical treatments effectively resolved alopecia and scalp psoriasis in a woman with Crohn's disease.

This review discusses common skin eruptions caused by biologics in treating inflammatory bowel disease and proposes tailored therapeutic approaches for managing these adverse reactions.

This study found that 17β-estradiol inhibited RANTES production in human keratinocytes by suppressing nuclear factor κB activity, suggesting a potential mechanism for 17β-estradiol's modulation of psoriasis-related inflammation.

This article reviews new drug combinations and unique agents for rheumatoid arthritis but reports no clinical results; the authors highlight several promising compounds awaiting approval.

This article discusses adverse immune-mediated skin reactions associated with TNF-alpha inhibitors, highlighting paradoxical reactions such as psoriasis that occur despite being treated with medications intended to alleviate the condition.

Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.

This study observed that among male patients who experienced telogen effluvium after platelet-rich plasma treatment for androgenic alopecia, there were elevated levels of TNF-α, androgen receptors, and altered 5α-reductase gene expression, suggesting these factors as potential contributors to this unintended outcome.

This review explores the role of neutrophil recruitment in the inflammation seen in hidradenitis suppurativa and emphasizes potential therapeutic targets within these pathways, but it reports no new clinical results.

This systematic review identified several factors contributing to increased cardiovascular risk in women with polycystic ovary syndrome, including insulin resistance, obesity, inflammation markers, and microbiota alterations linked to elevated trimethylamine-N-oxide levels.

This article examines anticytokine therapies for autoimmune diseases, highlighting the potential of anti-interferon-γ as a universal treatment for certain conditions and noting varying effectiveness of tumor necrosis factor-α inhibitors.

This study found that EGFR inhibitors and ligands did not significantly affect the expression of inflammatory biomarkers in cultured sebocytes, except for a notable increase in IL-1 expression with EGF treatment.

Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.

This review discusses different types of alopecia associated with psoriasis and highlights that hair loss in psoriasis is typically non-scarring and reversible, while also noting the increased risk of alopecia areata in these patients.

This study observed that in vitro exposure to dihydrotestosterone worsened COVID-19 spike protein-induced endothelial injury, while spironolactone showed potential in reducing this effect, suggesting a rationale for further evaluation in treating COVID-19.

This abstract describes a program with various presentations and events focused on Canadian excellence in rheumatology but reports no new research findings.

This study documented the progression of exfoliative cutaneous lupus erythematosus in German shorthaired pointers and found generally poor responses to therapies, including immunomodulatory drugs and a TNF-α inhibitor.

This study reviews the efficacy and safety of advanced therapies like TNFα inhibitors and IL-17/IL-23 inhibitors for dissecting cellulitis of the scalp, finding TNFα inhibitors particularly effective for severe or refractory cases, although prospective validation is needed for early intervention benefits.

IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

This study found that fig leaf extract significantly downregulated inflammatory and androgenic gene expression in vitro, suggesting potential topical benefits for certain skin disorders.

This study suggests that lithocholic acid may enhance hair regeneration in alopecia by activating vitamin D receptors in human dermal papilla cells.

This study found that UV-B exposure significantly increased the expression of inflammatory cytokines IL-1β and IL-8 in cultured sebocytes.

This case report highlights a woman who developed new-onset alopecia areata after starting adalimumab for psoriatic arthritis, challenging the assumed role of TNF-alpha in the condition's pathogenesis.